Hostname: page-component-74656f9884-8r8nv Total loading time: 0 Render date: 2026-11-08T02:26:14.679Z Has data issue: false hasContentIssue false

Molecular and cellular pathobiology of Ehrlichia infection: targets for new therapeutics and immunomodulation strategies

Published online by Cambridge University Press:  31 January 2011

Jere W. McBride
Affiliation:
Department of Pathology, Center for Emerging Infectious Diseases and Biodefense, Sealy Center for Vaccine Development, and the Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
David H. Walker*
Affiliation:
Department of Pathology, Center for Emerging Infectious Diseases and Biodefense, Sealy Center for Vaccine Development, and the Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
*
*Corresponding author: David H. Walker, Department of Pathology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0609, USA. E-mail: dwalker@utmb.edu
Rights & Permissions [Opens in a new window]

Abstract

Ehrlichia are small obligately intracellular bacteria in the order Rickettsiales that are transmitted by ticks and associated with emerging life-threatening human zoonoses. Vaccines are not available for human ehrlichiosis, and therapeutic options are limited to a single antibiotic class. New technologies for exploring host–pathogen interactions have yielded recent advances in understanding the molecular interactions between Ehrlichia and the eukaryotic host cell and identified new targets for therapeutic and vaccine development, including those that target pathogen virulence mechanisms or disrupt the processes associated with ehrlichial effector proteins. Animal models have also provided insight into immunopathological mechanisms that contribute significantly to understanding severe disease manifestations, which should lead to the development of immunomodulatory approaches for treating patients nearing or experiencing severe disease states. In this review, we discuss the recent advances in our understanding of molecular and cellular pathobiology and the immunobiology of Ehrlichia infection. We identify new molecular host–pathogen interactions that can be targets of new therapeutics, and discuss prospects for treating the immunological dysregulation during acute infection that leads to life-threatening complications.

Information

Type
Review Article
Copyright
Copyright © Cambridge University Press 2011
Figure 0

Figure 1. Immunogold-labelled electron micrograph of Ehrlichia chaffeensis TRP47. Within innate immune cells, ehrlichiae form membrane-bound microcolonies termed morulae. Individual ehrlichiae show two morphological forms: dense-cored cells (DC; 0.4–0.6 µm in diameter) and reticulate cell (R) forms (0.4–0.6 µm by 0.7–1.9 µm). Reticulate cells and dense-cored cells can be distinguished by the differential expression and secretion of two tandem-repeat-containing surface proteins – TRP47 and TRP120 – which are found only on dense-cored cells (Refs 13, 14). The intramorular space in some morulae contains a fibrillar matrix of ehrlichial origin (Ref. 15). Figure reproduced, with permission from American Society for Microbiology, from Ref. 14 (© 2006, American Society for Microbiology).

Figure 1

Figure 2. Developmental cycle of Ehrlichia chaffeensis in the eukaryotic host cell. Infectious dense-cored (DC) ehrlichiae attach and enter the host cell through receptor-mediated endocytosis, and within 1 h after entry transform into the intermediate (IM) 1, and then into the reticulate cell (RC). During the next 48 h RC replicates, doubling every 8 h, and then transforms into IM2 and matures to DC ehrlichiae within 72 h after initial cell contact (Ref. 16). DC ehrlichiae obtained 72 h post-infection showed much higher infectivity than E. chaffeensis RCs obtained 24 h post-infection. RC and DC ehrlichiae can be distinguished by two differentially expressed tandem repeat proteins – TRP47 and TRP120 – that are found only on DC ehrlichiae, and the major outer membrane protein p28-19, which is expressed only on the RC (Ref. 16). However, intermediate, presumably transitional, forms that co-express these proteins have also been described (Ref. 16). Although ehrlichiae and chlamydiae have similar morphological forms and developmental cycles, homologous genes for the histone H1 homologue proteins (Hc1 and Hc2) involved in condensation and decondensation of the chlamydial nucleoid are not present in the E. chaffeensis genome (Ref. 16). Figure adapted, with permission from John Wiley and Sons (http://www.interscience.wiley.com), from Ref. 16 (© The Authors).

Figure 2

Figure 3. Colocalisation of PCGF5 and IGLL1 with Ehrlichia chaffeensis expressing TRP47 within infected THP-1 cells.E. chaffeensis-infected cells were dually labelled with anti-TRP47 (green) and PCGF5 or IGLL1 (red) and examined by confocal microscopy. PCGF5 and IgLL1 colocalise with E. chaffeensis TRP47-labelled morulae (yellow, right merged panels). Molecular interactions between PCGF5, IGLL1, FYN, CAP1 and PTPN2 were first reported in Ref. 32. Abbreviations: IGLL1, immunoglobulin lambda-like polypeptide 1; PCGF5, polycomb group ring finger 5; THP-1 cells, a human acute monocytic leukaemia cell line; TRP47, tandem repeat protein 47.

Figure 3

Figure 4. A proposed model of TRP47 effector function in Ehrlichia chaffeensis infection of the macrophage. The schematic diagram is based on defined pathogen effector molecular interactions (Ref. 32) and previous reports of cellular events during infection (Refs 16, 52, 54, 56, 74). (a) Entry of Ehrlichia. Binding of E. chaffeensis to its receptor on the surface of an innate immune cell such as a monocyte directly or indirectly activates FYN. Activated (phosphorylated) FYN tyrosine kinase phosphorylates and activates PLCγ, which hydrolyses membrane phospholipid phosphatidylinositol (3,4)-bisphosphate (not shown), resulting in increased levels of inositol (1,4,5)-trisphosphate (IP3) and thus release of Ca2+ from intracellular stores and Ca2+ influx. FYN might regulate the function of the IP3 receptor by phosphorylation and promoting release of Ca2+ from the endoplasmic reticulum. FYN also phosphorylates caveolin-1 involved in ehrlichial entry. (b) TRP47–CAP1 interactions. TRP47 is secreted by dense-cored Ehrlichia and associated with the morula surface, where it interacts with CAP1. This interaction might facilitate endocytosis and vesicle trafficking, because CAP1 promotes rapid actin dynamics in conjunction with ADF/cofilin and is required for cell morphology, migration and endocytosis; in addition, the TRP47–CAP1 interaction might promote apoptosis in the late stages of infection (which could have an important role in the release of dense-cored ehrlichiae), because mitochondrial shuttling of CAP1 promotes actin- and coflin-dependent apoptosis. (c) TRP47–PCGF5 and TRP47–PTPN2 interactions. TRP47–PCGF5 interaction modulates gene transcription associated with cell signalling and remodelling of the cytoskeleton, facilitating and supporting intracellular survival of E. chaffeensis. TRP47– PTPN2 interaction might modulate cytokine signalling events by exerting negative feedback on the JAK–STAT pathway by dephosphorylation of JAKs and STATs involved in intravacuolar maintenance and survival of E. chaffeensis. Dashed lines indicate processes the JAK–STAT pathway might affect indirectly. Abbreviations: CAP1, adenylate cyclase-associated protein 1; ER, endoplasmic reticulum; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; PCGF5, polycomb group ring finger 5; PLCγ: phospholipase Cγ; PTPN2, protein tyrosine phosphatase, non-receptor type 2; STAT, signal transducer and activator of transcription; TRP47, tandem repeat protein 47.

Figure 4

Table 1. Selected E. chaffeensis Ank200 target genes identified by ChIP-on-chipa